Yanlan Wang | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Yanlan Wang | Cancer Cell Biology | Best Researcher Award

Dr. Yanlan Wang, Stanford, United States

Dr. Yanlan Wang is a distinguished postdoctoral research fellow at Stanford University’s Department of Pathology. She works in the esteemed Dr. Gerald Crabtree’s lab, where her research revolves around leveraging molecular glues to reprogram cancer drivers and trigger apoptosis. With a strong background in immuno-oncology, antibody engineering, and small molecule therapeutics, Dr. Wang has made significant contributions to targeted cancer therapies. Her interdisciplinary collaborations, notably with Dr. Nathanael Gray’s group, have explored the role of transcription factor complex-inducing compounds (TCIPs) in MLL-rearranged leukemia. Dr. Wang brings a rich international research experience from China and the U.S., with a career spanning translational medicine, biotechnology innovation, and academic excellence. She is known for her rigorous approach to scientific inquiry, collaborative spirit, and prolific publication record. Her passion for understanding and overcoming the mechanisms of cancer resistance positions her as a future leader in oncology drug development and precision medicine.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Outstanding Research Focus
    Dr. Wang’s work on molecular glues and transcription factor modulators represents cutting-edge approaches in cancer therapy, especially in targeting previously undruggable pathways.

  2. High Impact Publications
    With multiple first-author and co-corresponding author papers (e.g., J Immunol Methods 2025, Leukemia & Lymphoma 2020, Clin Pharmacol Ther 2021), Dr. Wang has demonstrated a strong track record in both fundamental and translational cancer research.

  3. Innovation & Translational Impact
    Her efforts in bispecific antibody engineering, IL-15 therapeutics, and AKR1C3-targeted prodrugs show clear applications in oncology drug development, bridging the lab and clinic.

  4. Prestigious Collaborations
    Collaborating with renowned researchers such as Dr. Gerald Crabtree and Dr. Nathanael Gray at Stanford indicates high confidence and integration in world-class research circles.

  5. Recognition & Awards
    She has received the Coxe Fellowship at Stanford and multiple merit-based scholarships, highlighting academic excellence and innovation.

  6. Leadership and Multidisciplinary Skills
    Dr. Wang has led several projects, authored high-level papers, and mentored junior researchers, showcasing both technical and leadership capability.

🔄 Areas for Improvement:

  1. Greater International Presentation Exposure
    Although she has strong publication credentials, more visibility through international oral presentations, keynote addresses, or panel roles would amplify her leadership profile.

  2. Independent Grant Record
    While she is currently in a postdoctoral role, seeking independent funding (e.g., K99/R00, early-career PI grants) would position her more competitively for independent investigator status.

  3. Patent or Commercial Translation
    Given the translational nature of her work, pursuit of intellectual property filings or biotech partnerships would further highlight impact.

🎓 Education:

Dr. Yanlan Wang began her academic journey at Xiangya School of Medicine, Central South University, where she earned her MBBS (M.D. equivalent) in June 2012. She continued at The Second Xiangya Hospital for her clinical residency, completing her M.S. in June 2015. Her pursuit of scientific excellence led her to earn a doctorate (M.D. equivalent to PhD) from Sun Yat-sen University in June 2018, with a research focus on microbial immunology and tumor biology. This diverse educational background gave her a solid foundation in both clinical medicine and biomedical research, allowing her to bridge translational gaps in cancer research. Her early training emphasized immunotherapy, molecular biology, and oncology, all of which paved the way for her postdoctoral work in cutting-edge labs. Her education reflects a consistent upward trajectory, marked by prestigious institutions, interdisciplinary training, and a seamless integration of clinical and scientific disciplines.

🔬 Experience:

Dr. Yanlan Wang is currently a postdoctoral research fellow in Dr. Gerald Crabtree’s lab at Stanford University, where she focuses on manipulating cancer cell pathways using molecular glues. Her prior research in China included pivotal roles in biotechnology innovation, including bispecific antibody engineering, prodrug design, and immune-oncology drug development. She has also collaborated extensively with Dr. Nathanael Gray’s lab at Stanford, exploring the therapeutic potential of TCIPs in leukemia. Dr. Wang’s hands-on experience includes multiplex screening platforms, flow cytometry, in vivo tumor models, and translational immunotherapy development. Over the years, she has taken leadership roles in preclinical projects, manuscript authorship, and international scientific presentations. Her diverse roles—from clinical residency to laboratory innovation—reflect her capability to translate complex scientific findings into therapeutic strategies. Dr. Wang has also mentored junior researchers and worked across multiple disciplines, underscoring her adaptability, leadership potential, and deep commitment to cancer research.

🏅 Awards and Honors:

Dr. Yanlan Wang’s excellence has been recognized through several prestigious awards. At Stanford, she received the Coxe Fellowship in 2021, honoring outstanding postdoctoral researchers. During her doctoral training, she earned the Special Award of Merit for the BJ-001 Project at BJ Bioscience Inc. in 2019 for her impactful translational research. Her academic merit was consistently acknowledged through the Bidi Scholarship (2016–2017) and Daxiang Scholarship (2015–2016) at Sun Yat-sen University. These honors underscore her commitment to scientific excellence, innovation, and translational impact in oncology and immunotherapy. Her ability to receive awards across both academic and industrial settings highlights her versatility and the real-world relevance of her work. These distinctions serve as a testament to her leadership in cancer drug development, collaborative effectiveness, and contribution to next-generation therapeutic discoveries.

🔍 Research Focus:

Dr. Yanlan Wang’s research lies at the intersection of cancer biology, molecular pharmacology, and immunotherapy. At Stanford, she investigates how molecular glues can be used to hijack cancer drivers and activate apoptosis, offering a novel route for targeted cancer therapies. Her work involves multiplex molecular glue screening, understanding protein degradation pathways, and designing synthetic lethality strategies. In collaboration with Dr. Nathanael Gray, she is also studying Transcription factor Complex-Inducing Compounds (TCIPs) for the treatment of MLL-rearranged leukemia, a particularly aggressive form of blood cancer. Prior to this, her research focused on bispecific antibodies, prodrugs, and IL-15 based immunotherapeutics, with a vision to decouple efficacy from toxicity. Through a blend of basic science and translational applications, she aims to rewire oncogenic signaling pathways and enhance anti-tumor immunity. Her research combines drug discovery, systems biology, and precision oncology, pushing the boundaries of targeted cancer treatment.

📚 Publications Top Notes:

  1. 🔬 Quantitative flow cytometry using quantitative streptavidin-protein G-biotin beads (qBeads) – J Immunol Methods, 2025

  2. 🧬 A Bivalent Molecular Glue Linking Lysine Acetyltransferases to Oncogene-directed Cell Death – Cell (revising)

  3. 💉 Enhance IL15 anti-tumor efficacy by inhibiting its negative feedback mechanism – (in preparation)

  4. ⚛️ Decouple the toxicity and efficacy of BJ-001, an integrin targeting IL-15 – AACR Abstract, 2019

  5. 🔄 Decoupling the toxicity and efficacy of immunotherapeutics – SITC Abstract, 2019

  6. 🧪 An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL – Leukemia & Lymphoma, 2020

  7. 🧫 A novel AKR1C3 specific prodrug TH3424 with potent anti-tumor activity in liver cancer – Clin Pharmacol Ther, 2021

  8. 🧲 A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity – J Vis Exp, 2018

  9. 🧠 Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies – Cancer Biol Ther, 2020

  10. 🧿 Bp-Bs, a novel T-cell engaging bispecific antibody with biparatopic Her2 binding – Mol Ther Oncolytics, 2019

  11. 🧰 A novel multi-functional anti-CEA-IL15 molecule displays potent anti-tumor activities – Drug Des Devel Ther, 2018

  12. 🧠 A single domain based anti-Her2 antibody has potent anti-tumor activities – Transl Oncol, 2018

🧾 Conclusion:

Dr. Yanlan Wang is highly deserving of the Best Researcher Award. Her contributions to cancer therapeutics through novel molecular approaches, her collaborations with globally renowned labs, and her publication record reflect a researcher of exceptional caliber and promise. With a deep understanding of tumor biology, a commitment to innovation, and a growing leadership presence in oncology research, she is not only suitable for the award but stands as a strong role model for future biomedical researchers.

Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Published on by Cell Biologist

Prof. Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Prof. Dalia Saleh, National Research Centre, Egypt

Dr. Dalia Osama Abd El Fattah Saleh is a distinguished pharmacologist and professor at the National Research Centre, Cairo, Egypt. With a career spanning over two decades in academic and pharmaceutical research, she specializes in molecular pharmacology, experimental therapeutics, and drug development. She earned her Ph.D. and M.Sc. in Pharmacology from Cairo University, where she also completed her undergraduate pharmacy degree with honors. Dr. Saleh’s prolific contributions to science are reflected in her extensive publication record, focusing on novel therapeutic strategies against various toxicological, metabolic, and inflammatory disorders. Her collaborative efforts have led to advancements in drug signaling pathways, phytochemical pharmacology, and nanotechnology-based delivery systems. Recognized nationally for her innovation, she has received several prestigious awards. Dr. Saleh continues to shape pharmacological research through her dedication to translational science, mentorship, and participation in international seminars and training programs.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  • Extensive Academic Background: Holds a Ph.D., M.Sc., and B.Sc. in Pharmacology from Cairo University, with a clear focus on endocrine and vascular pharmacology from early in her career.

  • Distinguished Research Record: Authored over 25+ high-impact publications in peer-reviewed journals including Scientific Reports, Toxicology Reports, Biochemistry and Cell Biology, and Environmental Science and Pollution Research.

  • Novel Scientific Contributions:

    • Explores molecular pharmacology through cutting-edge therapeutic approaches like AMPK/mTOR signaling, Nrf2/NF-κB modulation, and natural compound pharmacodynamics.

    • Studies involve both synthetic and phytochemical-based interventions, representing a hybrid and innovative research style.

  • Awards and Recognition:

    • National recognition for her research quality and productivity by the National Research Centre, with awards received in 2015 and 2020.

    • Ranked 24th in the institution for publication volume in 2014—an indicator of sustained output.

  • Global Exposure: Participated in professional training programs at King’s College London, enhancing her knowledge in clinical drug development and data management—an asset for interdisciplinary and translational research.

  • Leadership and Longevity: Promoted through all academic ranks at NRC, from Research Assistant to Professor, demonstrating not only competence but leadership and mentorship over time.

Areas for Improvement:

  • Clinical Translation: While the preclinical research is extensive, initiating clinical trials or translational studies would further strengthen the real-world applicability of her findings.

  • Global Visibility: Although trained internationally, more international speaking engagements, keynote invitations, or editorial roles could enhance global recognition.

  • Interdisciplinary Projects: Expanding collaborations across fields such as bioinformatics or biotechnology could amplify the innovation aspect of her work.

🎓 Education:

Dr. Dalia Saleh obtained all her academic degrees from Cairo University’s esteemed Faculty of Pharmacy. She was awarded her Ph.D. in Pharmacology in 2012 for her thesis examining estrogen’s vascular effects in insulin-resistant, ovariectomized rats. Earlier, she earned her M.Sc. in 2009 with research on rosiglitazone’s effects in streptozotocin-induced vascular changes. Her academic journey began with a B.Sc. in Pharmacy in 2002, graduating with distinction and honors. Her strong educational foundation laid the groundwork for her innovative and interdisciplinary research spanning molecular pharmacology, toxicology, and metabolic disorders. Through continuous professional development, including modules at King’s College London, Dr. Saleh stays aligned with global standards in pharmacological science and clinical drug development. Her educational background combines academic excellence with practical research expertise, making her well-equipped to address complex biomedical challenges.

👩‍🔬 Experience:

Dr. Dalia Saleh has built a progressive research career at Egypt’s National Research Centre, beginning as a Research Assistant in 2003. Over the years, she rose through the ranks to become a Professor in 2022. She previously held positions as Researcher (2012–2017) and Assistant Professor (2017–2022). Throughout her tenure, she has actively contributed to preclinical pharmacology research, focusing on inflammation, neuroprotection, metabolic diseases, and organ toxicity. Her interdisciplinary approach integrates pharmacodynamics, molecular signaling, and therapeutic intervention studies using both synthetic and natural compounds. She has led numerous studies that explore drug mechanisms at cellular and systemic levels, often employing rodent disease models. Dr. Saleh’s active participation in international training (e.g., at King’s College London) highlights her global engagement and commitment to continuous learning. Her career reflects not only research productivity but also leadership in collaborative scientific initiatives and mentoring of emerging researchers.

🏆 Awards & Honors:

Dr. Dalia Saleh has received multiple accolades that underscore her impact in the field of pharmacology. She was honored with the 2020 Scientific Pioneers Award and the 2015 Scientific Encouragement Award from Egypt’s National Research Centre (NRC), recognizing her outstanding research contributions. In 2014, she received institutional recognition for both her high publication output (ranked 24th NRC-wide) and for publishing in a high-impact journal (impact factor 4.067). These achievements highlight her consistent scientific productivity and influence in biomedical research. Dr. Saleh’s awards reflect a career driven by innovation, rigor, and dedication to solving pressing health issues. Her work continues to be widely cited and applied in translational pharmacology, securing her reputation as a leading figure in her discipline. She remains an inspiration to peers and students alike, with a legacy of both scientific excellence and mentorship.

🔬 Research Focus:

Dr. Dalia Saleh’s research is rooted in experimental pharmacology, with an emphasis on cell signaling pathways, drug discovery, and natural compound pharmacodynamics. She investigates molecular mechanisms underlying chronic diseases such as diabetes, hepatic and renal injury, neurodegeneration, and inflammatory disorders. A recurring theme in her work is the modulation of key signaling axes (e.g., AMPK/mTOR, NF-κB, PI3K/Akt) in mitigating organ toxicity and disease progression. Her recent studies explore the pharmacological potential of phytochemicals, drug hybrids, and nanoformulations in preclinical models. Dr. Saleh also examines gender-specific pathophysiology, as seen in her Ph.D. research on estrogen’s role in vascular dysfunction. She actively integrates biochemical, histological, and behavioral endpoints to ensure translational relevance. By bridging traditional medicine and molecular pharmacology, her work contributes to next-generation therapeutics and precision medicine. Her research has both national and global impact, frequently published in high-tier journals and cited in clinical research discussions.

📚 Publications Top Notes:

  1. 🧬 Eugenol alleviates acrylamide-induced testicular toxicity via AMPK/pAKT/mTOR signaling – Scientific Reports, 2024

  2. 💊 Trimetazidine protects against cisplatin-induced neuropathy via AMPK and Nrf2 pathways – Biochemistry and Cell Biology, 2023

  3. 🧪 Chromone-thiazolopyrimidine hybrids inhibit TNF-α, IL-6, and PGE2 – Polycyclic Aromatic Compounds, 2023

  4. 🧻 Chrysin counters cyclophosphamide-induced cystitis via STAT-3 and NF-κB inhibition – Chemico-Biological Interactions, 2023

  5. 🩺 Linagliptin and L-arginine synergize in hyperacidity via EP4 upregulation – Naunyn-Schmiedeberg’s Archives of Pharmacology, 2023

  6. 🧠 L-arginine protects against hepatic encephalopathy via anti-apoptotic mechanisms – Environmental Science and Pollution Research, 2023

  7. 🌿 Calotropis procera seed oil shows anti-inflammatory and antiparasitic activity – Arabian Journal of Chemistry, 2022

  8. 🧫 Olmesartan mitigates diabetic nephropathy through TLR4/P38-MAPK modulation – European Journal of Pharmacology, 2022

  9. 🌱 Anti-fibrotic activities of Plumbago species in liver fibrosis models – Scientific Reports, 2022

  10. 🐟 Omega-3 fatty acids protect against doxorubicin-induced liver damage – Saudi Journal of Biological Sciences, 2022

Conclusion:

Dr. Dalia O. Saleh is highly suitable for the Best Researcher Award based on her prolific scientific contributions, consistent academic progression, and commitment to impactful pharmacological research. Her strength lies in combining rigorous mechanistic studies with applied therapeutic exploration, especially in inflammation, oxidative stress, and natural product pharmacology.